Hualan Vac(SZ:301207) Xin Lang Cai Jing·2026-01-05 05:23Group 1 - The core viewpoint of the news is that Hualan Biological Engineering Inc. has seen a stock price increase of 5.05%, reaching 19.57 CNY per share, with a trading volume of 1.26 billion CNY and a turnover rate of 1.09%, resulting in a total market capitalization of 11.762 billion CNY [1] - Hualan Biological Engineering Inc. is located in Xinxiang, Henan Province, and was established on November 9, 2005. The company was listed on February 18, 2022, and its main business involves the research, production, and sales of human vaccines. The revenue composition is 98.11% from vaccine products and 1.89% from other sources [1] Group 2 - From the perspective of Hualan's top ten circulating shareholders, a fund under Southern Fund ranks among them. The Southern CSI 1000 ETF (512100) reduced its holdings by 8,700 shares in the third quarter, holding a total of 1.6522 million shares, which accounts for 0.28% of the circulating shares. The estimated floating profit today is approximately 1.5531 million CNY [2] - The Southern CSI 1000 ETF (512100) was established on September 29, 2016, with a latest scale of 76.63 billion CNY. Year-to-date, it has achieved a return of 29.23%, ranking 1828 out of 4189 in its category. Over the past year, it has also returned 29.23%, maintaining the same ranking [2] - The fund manager of Southern CSI 1000 ETF (512100) is Cui Lei, who has a cumulative tenure of 7 years and 61 days. The total asset scale under his management is 122.76 billion CNY, with the best fund return during his tenure being 208.53% and the worst being -15.93% [2]